UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF ILLINOIS 

EASTERN DIVISION 

In re NEBIVOLOL (’040) PATENT 

LITIGATION 

gm 

Civil Action No. 1:12-cv-5026 (EEB) (JC) 

MDL No. 2364 

JOINT REPORT ON THE NATURE AND FORM OF THE CLAIM CONSTRUCTION 

HEARING AND JOINT CLAIM CONSTRUCTION CHART

Pursuant to Local Patent Rule 4.2(f), Plaintiffs Forest Laboratories, Inc. and Forest 

Laboratories Holdings, Ltd. and Defendants Watson Laboratories, Inc. (NV), Watson 

Laboratories, Inc. (DE), Watson Laboratories, Inc. (NY), Watson Laboratories, Inc. (CT), 

Actavis Pharma, Inc., Actavis, Inc., Amerigen Pharmaceuticals, Inc., and Amerigen 

Pharmaceuticals Ltd. jointly submit their Report on the Nature and Form of the Claim 

Construction Hearing. The parties’ Joint Claim Construction Chart is attached to this report as 

Exhibit A. 

The Court has scheduled a Claim Construction Tutorial for July 19, 2013 at 1:30 p.m. and 

a Claim Construction Hearing for July 26, 2013 at 1:00 p.m. (D.I. 128, 135.) The parties 

propose that the tutorial follow the general format discussed at the January 25, 2013 status 

hearing: each side will present for one hour through a combination of attorneys and/or experts, 

and the tutorial will be on the record but may not be used in the litigation for any purpose. (D.I. 

119.) Defendants will present first, and each side may reserve a portion of its time for rebuttal. 

The parties propose that the Claim Construction Hearing proceed as follows: each side 

will have one hour and fifteen minutes to present through attorneys only. Defendants will 

present first, and each side may reserve a portion of its time for rebuttal. 

Case: 1:12-cv-05026 Document #: 143 Filed: 07/16/13 Page 1 of 4 PageID #:7731
2 

Dated: July 16, 2013 

 

Respectfully submitted, 

s/ Steven J. Horowitz 

David T. Pritikin 

Linda R. Friedlieb 

Steven J. Horowitz 

SIDLEY AUSTIN LLP 

1 S. Dearborn Street 

Chicago, Illinois 60603 

(312) 853-7000 

(312) 853-7036 (Fax) 

dpritikin@sidley.com 

lfriedlieb@sidley.com 

shorowitz@sidley.com 

Todd L. Krause 

SIDLEY AUSTIN LLP 

787 Seventh Avenue 

New York, New York 10019 

(212) 839-5300 

(212) 839-5599 (Fax) 

tkrause@sidley.com 

Attorneys for Plaintiffs Forest Laboratories, 

Inc. and Forest Laboratories Holdings, Ltd. 

Dated: July 16, 2013 

 

Respectfully submitted, 

s/ Jeremy Edwards 

Steven A. Maddox 

Jeremy Edwards 

KNOBBE MARTENS 

1717 Pennsylvania Avenue, N.W. 

Suite 900 

Washington, DC 20006 

steve.maddox@knobbe.com 

jeremy.edwards@knobbe.com 

Frederick Christopher Laney 

Ashley Elizabeth LaValley 

NIRO, HALLER & NIRO 

181 W. Madison 

Suite 6400 

Chicago, IL 60602 

laney@nshn.com 

alavalley@nshn.com 

Attorneys for Defendants Watson Laboratories 

Inc. (NV), Watson Laboratories Inc. (DE), 

Watson Laboratories Inc. (NY), Watson 

Laboratories Inc. (CT), Actavis Pharma, Inc., 

and Actavis, Inc.

Case: 1:12-cv-05026 Document #: 143 Filed: 07/16/13 Page 2 of 4 PageID #:7732
3 

s/ Christopher Casieri 

William D. Hare 

Steven M. War 

Christopher Casieri 

MCNEELY HARE & WAR LLP 

5335 Wisconsin Avenue, NW 

Suite 440 

Washington, DC 20015 

bill@miplaw.com 

steve@miplaw.com 

chris@miplaw.com 

Deirdre Anne Fox 

SCHARF BANKS MARMOR LLC 

333 West Wacker Drive 

Suite 450 

Chicago, IL 60606 

dfox@scharfbanks.com 

Attorneys for Defendants Amerigen 

Pharmaceuticals Inc. and Amerigen 

Pharmaceuticals Ltd.

 

Case: 1:12-cv-05026 Document #: 143 Filed: 07/16/13 Page 3 of 4 PageID #:7733
EXHIBIT A: JOINT CLAIM CONSTRUCTION CHART 

The disputed claim terms in U.S. Patent No. 6,545,040, along with the parties’ proposed 

constructions, are as follows: 

Claim Term Plaintiffs’ Proposed 

Construction 

Defendants’ Proposed 

Construction 

“consisting of” 

A transitional phrase that limits the 

claim to the recited elements, 

but does not exclude impurities 

ordinarily associated therewith, 

and allows for elements unrelated 

to the claimed invention 

Transition phrase that limits the 

claim to the recited elements, 

excludes any unrecited 

stereoisomers of nebivolol, 

and otherwise allows for elements 

unrelated to the claimed invention 

“potentiating” Enhancing or increasing 

Increasing the activity of another 

ingredient where the combined 

activity is more than the additive 

activity of each ingredient alone, 

i.e., a synergistic effect 

“active ingredients” 

Ingredients that furnish 

pharmacological activity or other 

direct effect in the diagnosis, cure, 

mitigation, treatment, or 

prevention of disease 

Ingredients having 

pharmacological activity 

Case: 1:12-cv-05026 Document #: 143 Filed: 07/16/13 Page 4 of 4 PageID #:7734